{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:03:29Z","timestamp":1790413409341,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11864-020-00813-0","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:02:50Z","timestamp":1610629370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-9951","authenticated-orcid":false,"given":"Janet","family":"Hardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellar P","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"3","key":"813_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1049909110361228","volume":"27","author":"SK Ang","year":"2010","unstructured":"Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010;27(3):219\u201325.","journal-title":"Am J Hosp Palliat Care"},{"issue":"6","key":"813_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s005200000151","volume":"8","author":"MP Davis","year":"2000","unstructured":"Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Support Care Cancer. 2000;8(6):444\u201352.","journal-title":"Support Care Cancer"},{"issue":"5","key":"813_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2-5-319","volume":"2","author":"K Mystakidou","year":"1997","unstructured":"Mystakidou K, Befon S, Trifyllis J, Liossi C, Papadimitriou J. Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. Oncologist. 1997;2(5):319\u201323.","journal-title":"Oncologist"},{"issue":"3","key":"813_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0885-3924(97)00349-7","volume":"15","author":"K Mystakidou","year":"1998","unstructured":"Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manag. 1998;15(3):176\u201384.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"813_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00520-004-0629-y","volume":"12","author":"P Glare","year":"2004","unstructured":"Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer. 2004;12(6):432\u201340.","journal-title":"Support Care Cancer"},{"key":"813_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-684X-12-2","volume":"12","author":"I Dietz","year":"2013","unstructured":"Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2.","journal-title":"BMC Palliat Care"},{"key":"813_CR7","first-page":"CD009420","volume":"11","author":"L Cox","year":"2015","unstructured":"Cox L, Darvill E, Dorman S. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database Syst Rev. 2015;11:CD009420.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"813_CR8","doi-asserted-by":"publisher","first-page":"e029942","DOI":"10.1136\/bmjopen-2019-029942","volume":"9","author":"JR Hardy","year":"2019","unstructured":"\u2022\u2022 Hardy JR, Skerman H, Philip J, et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. BMJ Open. 2019;9(9):e029942 A quality multicentre randomized controlled trial defing the antiemetic activity of levomepromazine.","journal-title":"BMJ Open"},{"issue":"6D","key":"813_CR9","first-page":"5209","volume":"23","author":"HL McCabe","year":"2003","unstructured":"McCabe HL, Maraveyas A. Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE). Anticancer Res. 2003;23(6D):5209\u201312.","journal-title":"Anticancer Res"},{"key":"813_CR10","doi-asserted-by":"crossref","unstructured":"ASCCemesis in advanced cancer patients: an open-label study. Palliat Med 2005; 19(1): 71\u20135.","DOI":"10.1191\/0269216305pm972oa"},{"issue":"4","key":"813_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/00004714-199908000-00012","volume":"19","author":"SN Ghaemi","year":"1999","unstructured":"Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol. 1999;19(4):354\u201361.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"813_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","volume":"25","author":"RS Keefe","year":"1999","unstructured":"Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2):201\u201322.","journal-title":"Schizophr Bull"},{"issue":"1","key":"813_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","volume":"37","author":"FP Bymaster","year":"1999","unstructured":"Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37(1):107\u201322.","journal-title":"Schizophr Res"},{"key":"813_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1192\/S0007125000293653","volume":"37","author":"F Bymaster","year":"1999","unstructured":"Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry Suppl. 1999;37:36\u201340.","journal-title":"Br J Psychiatry Suppl"},{"issue":"3","key":"813_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s002130050834","volume":"141","author":"W Zhang","year":"1999","unstructured":"Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141(3):267\u201378.","journal-title":"Psychopharmacology"},{"issue":"24","key":"813_CR16","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"key":"813_CR17","first-page":"CD012555","volume":"9","author":"A Sutherland","year":"2018","unstructured":"\u2022\u2022 Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018;9:CD012555 This reviewsupports the role of olanzapine as an antiemetic.","journal-title":"Cochrane Database Syst Rev"},{"key":"813_CR18","doi-asserted-by":"crossref","unstructured":"Zhou JG, Huang L, Jin SH, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020;5(1):e000621.","DOI":"10.1136\/esmoopen-2019-000621"},{"issue":"2","key":"813_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-020-0704-8","volume":"21","author":"RM Navari","year":"2020","unstructured":"Navari RM. Nausea and vomiting in advanced cancer. Curr Treat Options in Oncol. 2020;21(2):14.","journal-title":"Curr Treat Options in Oncol"},{"issue":"7","key":"813_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/jpm.2020.0101","volume":"23","author":"K Kaneishi","year":"2020","unstructured":"Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, et al. Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med. 2020;23(7):880\u20131.","journal-title":"J Palliat Med"},{"issue":"8","key":"813_CR21","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00520-018-4593-3","volume":"27","author":"S Harder","year":"2019","unstructured":"Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, et al. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Support Care Cancer. 2019;27(8):2849\u201356.","journal-title":"Support Care Cancer"},{"issue":"4","key":"813_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44(4):604\u20137.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"813_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0885-3924(03)00143-X","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag. 2003;25(6):578\u201382.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"813_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526\u201332.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"813_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12904-020-00559-4","volume":"19","author":"G Saudemont","year":"2020","unstructured":"Saudemont G, Prod\u2019Homme C, Da Silva A, et al. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020;19(1):56.","journal-title":"BMC Palliat Care"},{"key":"813_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6:895.","journal-title":"JAMA Oncol"},{"issue":"1","key":"813_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000358044","volume":"8","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Komuro K, Ohara K. Olanzapine and betamethasone are effective for the treatment of nausea and vomiting due to metastatic brain tumors of rectal cancer. Case Rep Gastroenterol. 2014;8(1):13\u20137.","journal-title":"Case Rep Gastroenterol"},{"issue":"2","key":"813_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/109662103764978506","volume":"6","author":"WC Jackson","year":"2003","unstructured":"Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6(2):251\u20135.","journal-title":"J Palliat Med"},{"issue":"3","key":"813_CR29","first-page":"349","volume":"33","author":"T Shinjo","year":"2006","unstructured":"Shinjo T, Okada M. Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho. 2006;33(3):349\u201352.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"5","key":"813_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jpainsymman.2010.02.017","volume":"40","author":"A Elsayem","year":"2010","unstructured":"Elsayem A, Bush SH, Munsell MF, Curry E III, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manag. 2010;40(5):774\u201382.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"813_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/0018578718823484","volume":"55","author":"MP Lorenzo","year":"2020","unstructured":"Lorenzo MP, Burgess J, Darko W. Intravenous olanzapine in a critically ill patient: an evolving route of administration. Hosp Pharm. 2020;55(2):108\u201311.","journal-title":"Hosp Pharm"},{"issue":"28","key":"813_CR32","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u201361.","journal-title":"J Clin Oncol"},{"issue":"4","key":"813_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","volume":"28","author":"E Bruera","year":"2004","unstructured":"Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28(4):381\u20138.","journal-title":"J Pain Symptom Manag"},{"issue":"25","key":"813_CR34","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","volume":"31","author":"S Yennurajalingam","year":"2013","unstructured":"Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076\u201382.","journal-title":"J Clin Oncol"},{"key":"813_CR35","doi-asserted-by":"publisher","unstructured":"\u2022 Vayne-Bossert P, Haywood A, Good P, Khan S, Rickett K, Jenkins-Marsh S, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemo- or radiotherapy, or surgery). Cochrane Libr. https:\/\/doi.org\/10.1002\/14651858.CD012002 Cochrane review on the role of corticosteroids for nausea not related to treatment.","DOI":"10.1002\/14651858.CD012002"},{"issue":"5","key":"813_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamaoncol.2016.0155","volume":"2","author":"G Wilkie","year":"2016","unstructured":"Wilkie G, Sakr B, Rizack T. Medical marijuana use in oncology: a review. JAMA Oncol. 2016;2(5):670\u20135.","journal-title":"JAMA Oncol"},{"issue":"11","key":"813_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/1060028020930189","volume":"54","author":"S Inglet","year":"2020","unstructured":"Inglet S, Winter B, Yost SE, Entringer S, Lian A, Biksacky M, et al. Clinical data for the use of cannabis-based treatments: a comprehensive review of the literature. Ann Pharmacother. 2020;54(11):1109\u201343.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"813_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/jcsm.12273","volume":"9","author":"M Mucke","year":"2018","unstructured":"Mucke M, Weier M, Carter C, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220\u201334.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"813_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/ph5050529","volume":"5","author":"S Zhornitsky","year":"2012","unstructured":"Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529\u201352.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"813_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","volume":"25","author":"D Walsh","year":"2016","unstructured":"\u2022\u2022 Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. Updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer 2017. 2016;25(1):333\u201340 Evidence-based guidelines for the management of nausea and vomiting not related to treatment.","journal-title":"Support Care Cancer 2017"},{"issue":"1","key":"813_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-018-4404-8","volume":"18","author":"J Hardy","year":"2018","unstructured":"\u2022\u2022 Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18(1):510 A paper that challenges the long-held views towards the best model for managing nausea and vomiting in palliative care.","journal-title":"BMC Cancer"},{"issue":"1","key":"813_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpainsymman.2009.11.321","volume":"40","author":"JR Hardy","year":"2010","unstructured":"Hardy JR, O\u2019Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manag. 2010;40(1):111\u20136.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"813_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1049909108315909","volume":"25","author":"G Kumar","year":"2008","unstructured":"Kumar G, Hayes KA, Clark R. Efficacy of a scheduled IV cocktail of antiemetics for the palliation of nausea and vomiting in a hospice population. Am J Hosp Palliat Care. 2008;25(3):184\u20139.","journal-title":"Am J Hosp Palliat Care"},{"issue":"6","key":"813_CR44","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1089\/jpm.2005.8.1135","volume":"8","author":"DJ Weschules","year":"2005","unstructured":"Weschules DJ. Tolerability of the compound ABHR in hospice patients. J Palliat Med. 2005;8(6):1135\u201343.","journal-title":"J Palliat Med"},{"issue":"1","key":"813_CR45","first-page":"27","volume":"6","author":"J Bleicher","year":"2008","unstructured":"Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea\/vomiting: results of two pilot trials. J Support Oncol. 2008;6(1):27\u201332.","journal-title":"J Support Oncol"},{"issue":"5","key":"813_CR46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jpainsymman.2014.02.010","volume":"48","author":"DS Fletcher","year":"2014","unstructured":"Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of topical \u201cABH Gel\u201d (Ativan((R)), Benadryl((R)), Haldol((R))) vs. placebo in cancer patients with nausea. J Pain Symptom Manag. 2014;48(5):797\u2013803.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"813_CR47","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jpainsymman.2011.05.017","volume":"43","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Ritter JK, Poklis JL, Fletcher D, Coyne PJ, Dodson P, et al. ABH gel is not absorbed from the skin of normal volunteers. J Pain Symptom Manag. 2012;43(5):961\u20136.","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"813_CR48","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jpainsymman.2009.08.010","volume":"39","author":"MP Davis","year":"2010","unstructured":"Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and\/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39(4):756\u201367.","journal-title":"J Pain Symptom Manag"},{"key":"813_CR49","doi-asserted-by":"crossref","unstructured":"\u2022 Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer . Cochrane Database Syst Rev. 2000;2000(2):CD001219.This oft quoted paper is the basis for the standard use of dexamethasone in malignant bowel obstruction, even though both studies included were underpowered.","DOI":"10.1002\/14651858.CD001219"},{"issue":"4","key":"813_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/1049909115569047","volume":"33","author":"J Berger","year":"2016","unstructured":"Berger J, Lester P, Rodrigues L. Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide. Am J Hosp Palliat Care. 2016;33(4):407\u201310.","journal-title":"Am J Hosp Palliat Care"},{"issue":"2","key":"813_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jpainsymman.2008.01.014","volume":"37","author":"A Tuca","year":"2009","unstructured":"Tuca A, Roca R, Sala C, Porta J, Serrano G, Gonz\u00e1lez-Barboteo J, et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manag. 2009;37(2):259\u201370.","journal-title":"J Pain Symptom Manag"},{"key":"813_CR52","doi-asserted-by":"crossref","unstructured":"Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manag. 2016;52(6):901\u201319 e1.","DOI":"10.1016\/j.jpainsymman.2016.05.032"},{"issue":"5","key":"813_CR53","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","volume":"49","author":"DC Currow","year":"2015","unstructured":"Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag. 2015;49(5):814\u201321.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"813_CR54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jpainsymman.2015.04.001","volume":"49","author":"S Mercadante","year":"2015","unstructured":"Mercadante S. Octreotide for malignant bowel obstruction: commentary on Currow et al. J Pain Symptom Manag. 2015;49(5):813.","journal-title":"J Pain Symptom Manag"},{"key":"813_CR55","doi-asserted-by":"crossref","unstructured":"Minoura T, Takeuchi M, Morita T, Kawakami K. Practice patterns of medications for patients with malignant bowel obstruction using a nationwide claims database and the association between treatment outcomes and concomitant use of H2-blockers\/proton pump inhibitors and corticosteroids with octreotide. J Pain Symptom Manag. 2018;55(2):413\u20139 e2.","DOI":"10.1016\/j.jpainsymman.2017.10.019"},{"issue":"2","key":"813_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jpainsymman.2019.12.304","volume":"59","author":"W Wey","year":"2020","unstructured":"Wey W, Mian M, Calabrese R, Walter M. Palliative medicine management of inoperable malignant bowel obstruction with \u2018triple therapy\u2019: dexamethasone,octreotide and metoclopramide at a comprehensive cancer center. J Pain Symptom Manag. 2020;59(2):552\u20133.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"813_CR57","first-page":"422","volume":"74","author":"WP Joyce","year":"1992","unstructured":"Joyce WP, Delaney PV, Gorey TF, Fitzpatrick JM. The value of water-soluble contrast radiology in the management of acute small bowel obstruction. Ann R Coll Surg Engl. 1992;74(6):422\u20135.","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"813_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00520-001-0332-1","volume":"10","author":"J Hardy","year":"2002","unstructured":"Hardy J, Daly S, McQuade B, Albertsson M, Chimontsi-Kypriou V, Stathopoulos G, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10(3):231\u20136.","journal-title":"Support Care Cancer"},{"issue":"9","key":"813_CR59","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1007\/s00520-019-4663-1","volume":"27","author":"R Giusti","year":"2019","unstructured":"Giusti R, Mazzotta M, Filetti M, Daniele G, Tsukuura H, Ficorella C, et al. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians\u2019 practice. Support Care Cancer. 2019;27(9):3531\u20135.","journal-title":"Support Care Cancer"},{"issue":"5","key":"813_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/0269216311404273","volume":"25","author":"EA Laugsand","year":"2011","unstructured":"Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442\u201353.","journal-title":"Palliat Med"},{"issue":"3","key":"813_CR61","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00520-019-04884-0","volume":"28","author":"J Sato","year":"2020","unstructured":"Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083\u20138.","journal-title":"Support Care Cancer"},{"key":"813_CR62","first-page":"CD004125","volume":"3","author":"JB Carlisle","year":"2006","unstructured":"Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006;3:CD004125.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"813_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2044.2003.03189_6.x","volume":"58","author":"CM O\u2019Brien","year":"2003","unstructured":"O\u2019Brien CM, Titley G, Whitehurst P. A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in children. Anaesthesia. 2003;58(7):707\u201311.","journal-title":"Anaesthesia"},{"issue":"5","key":"813_CR64","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/bja\/aeg120","volume":"90","author":"SA Nortcliffe","year":"2003","unstructured":"Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth. 2003;90(5):665\u201370.","journal-title":"Br J Anaesth"},{"issue":"4","key":"813_CR65","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1177\/0036933013508039","volume":"58","author":"J Woodfield","year":"2013","unstructured":"Woodfield J, St George EJ. Post-operative cyclizine misuse. Scott Med J. 2013;58(4):e1\u20132.","journal-title":"Scott Med J"},{"issue":"7","key":"813_CR66","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1177\/0269216308094337","volume":"22","author":"F Bailey","year":"2008","unstructured":"Bailey F, Davies A. The misuse\/abuse of antihistamine antiemetic medication (cyclizine) by cancer patients. Palliat Med. 2008;22(7):869\u201371.","journal-title":"Palliat Med"},{"key":"813_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CIA.S13109","volume":"6","author":"P Glare","year":"2011","unstructured":"Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243\u201359.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"813_CR68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00004850-199701000-00009","volume":"12","author":"L Pedersen","year":"1997","unstructured":"Pedersen L, Klysner R. Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Int Clin Psychopharmacol. 1997;12(1):59\u201360.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"813_CR69","doi-asserted-by":"publisher","first-page":"G796","DOI":"10.1152\/ajpgi.00130.2013","volume":"306","author":"J Yin","year":"2014","unstructured":"Yin J, Song J, Lei Y, Xu X, Chen JD. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(9):G796\u2013801.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"813_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, et al. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investig New Drugs. 2020;38(2):507\u201314.","journal-title":"Investig New Drugs"},{"issue":"12","key":"813_CR71","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-2044.2010.06561.x","volume":"65","author":"FL Chang","year":"2010","unstructured":"Chang FL, Ho ST, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery*. Anaesthesia. 2010;65(12):1206\u201311.","journal-title":"Anaesthesia"},{"key":"813_CR72","doi-asserted-by":"crossref","unstructured":"Chen CC, Lin CS, Ko YP, Hung YC, Lao HC, Hsu YW. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008;106(1):109\u201313 table of contents.","DOI":"10.1213\/01.ane.0000289636.09841.bc"},{"issue":"10","key":"813_CR73","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1381\/096089206778663634","volume":"16","author":"S Huerta","year":"2006","unstructured":"Huerta S, Siddiqui A. Intractable nausea and vomiting following Roux-en-Y gastric bypass: role of mirtazapine. Obes Surg. 2006;16(10):1399.","journal-title":"Obes Surg"},{"issue":"6","key":"813_CR74","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.pnpbp.2006.03.015","volume":"30","author":"CU Pae","year":"2006","unstructured":"Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30(6):1143\u20135.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"6","key":"813_CR75","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/psyg.12430","volume":"19","author":"JI Park","year":"2019","unstructured":"Park JI. Rapid improvement of functional nausea and vomiting with mirtazapine in an elderly patient. Psychogeriatrics. 2019;19(6):614\u20135.","journal-title":"Psychogeriatrics"},{"issue":"6","key":"813_CR76","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1272\/jnms.81.392","volume":"81","author":"J Song","year":"2014","unstructured":"Song J, Lin N, Tian F, Li Y, Li Y. Successful treatment of gastroparesis with the antidepressant mirtazapine: a case report. J Nippon Med Sch. 2014;81(6):392\u20134.","journal-title":"J Nippon Med Sch"},{"issue":"4","key":"813_CR77","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jopan.2018.11.006","volume":"34","author":"D Bhattacharjee","year":"2019","unstructured":"Bhattacharjee D, Doleman B, Lund J, Williams J. Mirtazapine for postoperative nausea and vomiting: systematic review, meta-analysis, and trial sequential analysis. J Perianesth Nurs. 2019;34(4):680\u201390.","journal-title":"J Perianesth Nurs"},{"issue":"4","key":"813_CR78","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1176\/appi.psy.41.4.356","volume":"41","author":"DS Thompson","year":"2000","unstructured":"Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics. 2000;41(4):356\u20139.","journal-title":"Psychosomatics"},{"issue":"3","key":"813_CR79","first-page":"329","volume":"41","author":"H Shibahara","year":"2014","unstructured":"Shibahara H, Uematsu N, Imai E, Tokura Y, Nishimura D. Effectiveness of mirtazapine for digestive symptoms in palliative care-retrospective study of 50 cases. Gan To Kagaku Ryoho. 2014;41(3):329\u201333.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"813_CR80","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/IJPC.IJPC_17_17","volume":"23","author":"N Kumar","year":"2017","unstructured":"Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017;23(3):335\u20137.","journal-title":"Indian J Palliat Care"},{"issue":"2","key":"813_CR81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/1049909109345685","volume":"27","author":"RP Riechelmann","year":"2010","unstructured":"Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27(2):106\u201310.","journal-title":"Am J Hosp Palliat Care"},{"issue":"5","key":"813_CR82","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0885-3924(02)00381-0","volume":"23","author":"DE Theobald","year":"2002","unstructured":"Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag. 2002;23(5):442\u20137.","journal-title":"J Pain Symptom Manag"},{"issue":"11","key":"813_CR83","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00520-008-0425-1","volume":"16","author":"ES Cankurtaran","year":"2008","unstructured":"Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16(11):1291\u20138.","journal-title":"Support Care Cancer"},{"issue":"10","key":"813_CR84","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00520-013-1846-z","volume":"21","author":"K Imai","year":"2013","unstructured":"Imai K, Ikenaga M, Kodama T, Kanemura S, Tamura K, Morita T. Sublingually administered scopolamine for nausea in terminally ill cancer patients. Support Care Cancer. 2013;21(10):2777\u201381.","journal-title":"Support Care Cancer"},{"key":"813_CR85","doi-asserted-by":"crossref","unstructured":"Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1\u20139 e1.","DOI":"10.1016\/j.annemergmed.2015.09.031"},{"issue":"6","key":"813_CR86","first-page":"417","volume":"75","author":"L Teran","year":"2007","unstructured":"Teran L, Hawkins JK. The effectiveness of inhalation isopropyl alcohol vs. granisetron for the prevention of postoperative nausea and vomiting. AANA J. 2007;75(6):417\u201322.","journal-title":"AANA J"},{"issue":"2","key":"813_CR87","first-page":"127","volume":"71","author":"AW Winston","year":"2003","unstructured":"Winston AW, Rinehart RS, Riley GP, Vacchiano CA, Pellegrini JE. Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea. AANA J. 2003;71(2):127\u201332.","journal-title":"AANA J"},{"key":"813_CR88","unstructured":"Schwartz A. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as high risk for developing PONV. AANA J. 2009;77(6):417\u20138 author reply 8."},{"issue":"4","key":"813_CR89","first-page":"293","volume":"77","author":"J Pellegrini","year":"2009","unstructured":"Pellegrini J, DeLoge J, Bennett J, Kelly J. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as at high risk for developing PONV. AANA J. 2009;77(4):293\u20139.","journal-title":"AANA J"},{"issue":"1","key":"813_CR90","first-page":"21","volume":"75","author":"JW Cotton","year":"2007","unstructured":"Cotton JW, Rowell LR, Hood RR, Pellegrini JE. A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. AANA J. 2007;75(1):21\u20136.","journal-title":"AANA J"},{"issue":"2","key":"813_CR91","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00520-016-3423-8","volume":"25","author":"L Thamlikitkul","year":"2017","unstructured":"Thamlikitkul L, Srimuninnimit V, Akewanlop C, Ithimakin S, Techawathanawanna S, Korphaisarn K, et al. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Support Care Cancer. 2017;25(2):459\u201364.","journal-title":"Support Care Cancer"},{"issue":"7","key":"813_CR92","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00520-019-05129-w","volume":"28","author":"R Bhargava","year":"2020","unstructured":"Bhargava R, Chasen M, Elten M, MacDonald N. The effect of ginger (Zingiber officinale Roscoe) in patients with advanced cancer. Support Care Cancer. 2020;28(7):3279\u201386.","journal-title":"Support Care Cancer"},{"issue":"22","key":"813_CR93","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1002\/cncr.28892","volume":"120","author":"DL Barton","year":"2014","unstructured":"Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, et al. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 2014;120(22):3575\u201383.","journal-title":"Cancer"},{"issue":"11\u201312","key":"813_CR94","first-page":"31","volume":"9","author":"DR Spiegel","year":"2012","unstructured":"Spiegel DR, Webb K. A case of treatment refractory hyperemesis gravidarum in a patient with comorbid anxiety, treated successfully with adjunctive gabapentin: a review and the potential role of neurogastroentereology in understanding its pathogenesis and treatment. Innov Clin Neurosci. 2012;9(11\u201312):31\u20138.","journal-title":"Innov Clin Neurosci"},{"issue":"8","key":"813_CR95","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.otsr.2019.09.023","volume":"105","author":"A Ul Huda","year":"2019","unstructured":"Ul Huda A, Jordan RW, Daggett M, Saithna A. Pre-medication with Gabapentin is associated with significant reductions in nausea and vomiting after shoulder arthroscopy: a meta-analysis. Orthop Traumatol Surg Res. 2019;105(8):1487\u201393.","journal-title":"Orthop Traumatol Surg Res"},{"issue":"37","key":"813_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008031","volume":"96","author":"B Liu","year":"2017","unstructured":"Liu B, Liu R, Wang L. A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery. Medicine (Baltimore). 2017;96(37):e8031.","journal-title":"Medicine (Baltimore)"},{"key":"813_CR97","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejogrb.2014.08.013","volume":"181","author":"T Guttuso Jr","year":"2014","unstructured":"Guttuso T Jr, Shaman M, Thornburg LL. Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;181:280\u20133.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"813_CR98","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s00221-014-3905-1","volume":"232","author":"T Guttuso Jr","year":"2014","unstructured":"Guttuso T Jr. Gabapentin\u2019s anti-nausea and anti-emetic effects: a review. Exp Brain Res. 2014;232(8):2535\u20139.","journal-title":"Exp Brain Res"},{"issue":"1","key":"813_CR99","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.earlhumdev.2009.11.003","volume":"86","author":"T Guttuso Jr","year":"2010","unstructured":"Guttuso T Jr, Robinson LK, Amankwah KS. Gabapentin use in hyperemesis gravidarum: a pilot study. Early Hum Dev. 2010;86(1):65\u20136.","journal-title":"Early Hum Dev"},{"issue":"12","key":"813_CR100","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.14309\/ajg.0000000000000458","volume":"114","author":"F Carbone","year":"2019","unstructured":"Carbone F, Van den Houte K, Goelen N, et al. Mechanism underlying symptom benefit with prucalopride in gastroparesis. Am J Gastroenterol. 2019;114(12):1920\u20131.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"813_CR101","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.14309\/ajg.0000000000000304","volume":"114","author":"F Carbone","year":"2019","unstructured":"Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019;114(8):1265\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"813_CR102","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/nmo.12663","volume":"27","author":"R Hobson","year":"2015","unstructured":"Hobson R, Farmer AD, Dewit OE, O\u2019Donnell M, Hacquoil K, Robertson D, et al. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015;27(11):1629\u201337.","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"813_CR103","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13054-016-1420-4","volume":"20","author":"MJ Chapman","year":"2016","unstructured":"Chapman MJ, Deane AM, O\u2019Connor SL, et al. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016;20(1):232.","journal-title":"Crit Care"},{"key":"813_CR104","doi-asserted-by":"crossref","unstructured":"Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016;151(1):87\u201396 e6.","DOI":"10.1053\/j.gastro.2016.03.038"},{"key":"813_CR105","doi-asserted-by":"crossref","unstructured":"Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, Placebo-Controlled Study. Gastroenterology. 2017;153(5):1240\u201350 e2.","DOI":"10.1053\/j.gastro.2017.07.035"},{"issue":"4","key":"813_CR106","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11938-016-0110-2","volume":"14","author":"WL Hasler","year":"2016","unstructured":"Hasler WL. Newest drugs for chronic unexplained nausea and vomiting. Curr Treat Options Gastroenterol. 2016;14(4):371\u201385.","journal-title":"Curr Treat Options Gastroenterol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00813-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T06:07:29Z","timestamp":1674886049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00813-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00813-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"20 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standard"}},{"value":"Janet Hardy has been supported by a grant from the Australian National Health and Medical Research Council (NHMRC), which funded a number of studies quoted in this article and undertaken by Dr. Hardy. Mellar P. Davis declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article contains studies with human subjects performed by Prof. Hardy and reviews published by Dr. Mellar and Prof. Hardy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"17"}}